Panbela Therapeutics, Inc.
PBLA · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $25,647 | $35,731 | $10,010 | $5,754 |
| Gross Profit | -$25,647 | -$35,731 | -$10,010 | -$5,754 |
| % Margin | – | – | – | – |
| R&D Expenses | $20,614 | $28,049 | $5,423 | $2,505 |
| G&A Expenses | $5,033 | $6,044 | $4,587 | $3,249 |
| SG&A Expenses | $5,033 | $6,044 | $4,587 | $3,249 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25,647 | $34,093 | $10,010 | $5,754 |
| Operating Income | -$51,294 | -$34,093 | -$10,010 | -$5,754 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $25,845 | -$956 | -$613 | $691 |
| Pre-Tax Income | -$25,449 | -$35,049 | -$10,623 | -$5,063 |
| Tax Expense | -$186 | -$116 | -$488 | -$295 |
| Net Income | -$25,263 | -$34,933 | -$10,135 | -$4,768 |
| % Margin | – | – | – | – |
| EPS | -232,429.55 | -40,748.57 | -20,773.7 | -14,798.1 |
| % Growth | -470.4% | -96.2% | -40.4% | – |
| EPS Diluted | -232,429.55 | -40,748.57 | -20,773.7 | -14,798.1 |
| Weighted Avg Shares Out | 0 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $123 | $14 | $1 | $0 |
| Interest Expense | -$317 | $288 | $11 | $17 |
| Depreciation & Amortization | -$25,528 | $16 | $10 | $0 |
| EBITDA | -$51,294 | -$34,745 | -$10,611 | -$5,046 |
| % Margin | – | – | – | – |